WST

SEC source: 0001562180-23-006236 · primarydocument.xml · nonDerivative · entry 3

Birkett Bernard · CIK 0001658001 · Sr VP, Chief Fin & Ops Off

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,566

F1 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $370.00 to $370.96, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.

SEC source: 0001562180-23-006236 · primarydocument.xml · nonDerivative · entry 2

Birkett Bernard · CIK 0001658001 · Sr VP, Chief Fin & Ops Off

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,700

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-23-006236 · primarydocument.xml · nonDerivative · entry 1

Birkett Bernard · CIK 0001658001 · Sr VP, Chief Fin & Ops Off

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,816

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-23-004627 · primarydocument.xml · derivative · entry 3

Witherspoon Charles · CIK 0001731739 · VP & Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,548

Underlying: Common Stock · 1,000 shares

Expires 2029-02-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-23-004627 · primarydocument.xml · nonDerivative · entry 2

Witherspoon Charles · CIK 0001731739 · VP & Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,829.4979

SEC source: 0001562180-23-004627 · primarydocument.xml · nonDerivative · entry 1

Witherspoon Charles · CIK 0001731739 · VP & Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,829.4979

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-23-004626 · primarydocument.xml · derivative · entry 3

Winters Chad · CIK 0001811424 · VP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 456

Underlying: Common Stock · 872 shares

Expires 2029-10-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-23-004626 · primarydocument.xml · nonDerivative · entry 2

Winters Chad · CIK 0001811424 · VP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,448.711

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-23-004626 · primarydocument.xml · nonDerivative · entry 1

Winters Chad · CIK 0001811424 · VP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,320.711

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-23-004067 · primarydocument.xml · derivative · entry 7

Green Eric Mark · CIK 0001336007 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 148,132

Underlying: Common Stock · 50,000 shares

Expires 2025-04-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_date: This option is fully vested.

SEC source: 0001562180-23-004067 · primarydocument.xml · nonDerivative · entry 6

Green Eric Mark · CIK 0001336007 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 134,574.0865

F2 · shares: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on 9/14/2022. The Rule 10b5-1 trading plan, which was structured to include several sale periods, was established as part of the Reporting Person's long-term strategy for asset diversification and financial, retirement, estate and tax planning activities over a period of time. In total, 50,000 options were exercised with 44,000 shares sold and 6,000 shares held by the reporting person.

F7 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $365.43 to $365.48, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.

SEC source: 0001562180-23-004067 · primarydocument.xml · nonDerivative · entry 5

Green Eric Mark · CIK 0001336007 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 135,074.0865

F2 · shares: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on 9/14/2022. The Rule 10b5-1 trading plan, which was structured to include several sale periods, was established as part of the Reporting Person's long-term strategy for asset diversification and financial, retirement, estate and tax planning activities over a period of time. In total, 50,000 options were exercised with 44,000 shares sold and 6,000 shares held by the reporting person.

F6 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $364.425 to $365.295, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.

SEC source: 0001562180-23-004067 · primarydocument.xml · nonDerivative · entry 4

Green Eric Mark · CIK 0001336007 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 139,207.0865

F2 · shares: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on 9/14/2022. The Rule 10b5-1 trading plan, which was structured to include several sale periods, was established as part of the Reporting Person's long-term strategy for asset diversification and financial, retirement, estate and tax planning activities over a period of time. In total, 50,000 options were exercised with 44,000 shares sold and 6,000 shares held by the reporting person.

F5 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $363.42 to $364.41, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.

SEC source: 0001562180-23-004067 · primarydocument.xml · nonDerivative · entry 3

Green Eric Mark · CIK 0001336007 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 151,855.0865

F2 · shares: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on 9/14/2022. The Rule 10b5-1 trading plan, which was structured to include several sale periods, was established as part of the Reporting Person's long-term strategy for asset diversification and financial, retirement, estate and tax planning activities over a period of time. In total, 50,000 options were exercised with 44,000 shares sold and 6,000 shares held by the reporting person.

F4 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $362.42 to $363.41, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.

SEC source: 0001562180-23-004067 · primarydocument.xml · nonDerivative · entry 2

Green Eric Mark · CIK 0001336007 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 164,417.0865

F2 · shares: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on 9/14/2022. The Rule 10b5-1 trading plan, which was structured to include several sale periods, was established as part of the Reporting Person's long-term strategy for asset diversification and financial, retirement, estate and tax planning activities over a period of time. In total, 50,000 options were exercised with 44,000 shares sold and 6,000 shares held by the reporting person.

F3 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $361.42 to $362.41, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.

SEC source: 0001562180-23-004067 · primarydocument.xml · nonDerivative · entry 1

Green Eric Mark · CIK 0001336007 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 178,574.0865

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The shares reported were acquired by the Reporting Person from exercising a portion of a stock option award expiring in 2025, pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was completed pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on 9/14/2022.

SEC source: 0001562180-23-004003 · primarydocument.xml · nonDerivative · entry 1

Winters Chad · CIK 0001811424 · VP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,448.711

F1 · kind: Shares withheld solely for the purpose of satisfying tax liability due upon vesting of restricted stock award.

SEC source: 0001562180-23-003794 · primarydocument.xml · derivative · entry 5

Favorite Annette F · CIK 0001654975 · Sr. VP & Chief HR Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 13,012 shares

Expires 2026-02-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-23-003794 · primarydocument.xml · nonDerivative · entry 4

Favorite Annette F · CIK 0001654975 · Sr. VP & Chief HR Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,876.9617

F3 · price: This transaction was executed in multiple trades at prices ranging from $367.03 USD to $367.98 USD; the price reported above reflects the weighted average sale price.

SEC source: 0001562180-23-003794 · primarydocument.xml · nonDerivative · entry 3

Favorite Annette F · CIK 0001654975 · Sr. VP & Chief HR Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,776.9617

F2 · price: This transaction was executed in multiple trades at prices ranging from $366.01 USD to $366.985 USD; the price reported above reflects the weighted average sale price.

SEC source: 0001562180-23-003794 · primarydocument.xml · nonDerivative · entry 2

Favorite Annette F · CIK 0001654975 · Sr. VP & Chief HR Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,463.9617

F1 · price: This transaction was executed in multiple trades at prices ranging from $365.00 USD to $365.97 USD; the price reported above reflects the weighted average sale price.

SEC source: 0001562180-23-003794 · primarydocument.xml · nonDerivative · entry 1

Favorite Annette F · CIK 0001654975 · Sr. VP & Chief HR Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,888.9617

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-23-003795 · primarydocument.xml · derivative · entry 4

Abraham Silji · CIK 0001733001 · SVP, Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,020 shares

Expires 2028-02-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: This award vests in 4 equal annual installments beginning on 2/26/2019.

SEC source: 0001562180-23-003795 · primarydocument.xml · nonDerivative · entry 3

Abraham Silji · CIK 0001733001 · SVP, Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,209.2997

F2 · price: The price reported in Column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $366.0350 to $366.18, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.

SEC source: 0001562180-23-003795 · primarydocument.xml · nonDerivative · entry 2

Abraham Silji · CIK 0001733001 · SVP, Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,858.2997

F1 · price: The price reported in Column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $365.00 to $365.91, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.

SEC source: 0001562180-23-003795 · primarydocument.xml · nonDerivative · entry 1

Abraham Silji · CIK 0001733001 · SVP, Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,229.2997

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-23-003796 · primarydocument.xml · nonDerivative · entry 1

Hofmann Thomas W · CIK 0001174597 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,616.39

F1 · price: The price reported in Column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $365.52 to $365.64, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.

SEC source: 0001562180-23-003706 · primarydocument.xml · nonDerivative · entry 1

Lockhart Stephen H · CIK 0001856013 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,070

F1 · price: These shares of restricted stock units will vest in full on the date of the next annual shareholder meeting.

SEC source: 0001562180-23-003705 · primarydocument.xml · nonDerivative · entry 1

Hofmann Thomas W · CIK 0001174597 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,828.39

F1 · price: These shares of restricted stock units will vest in full on the date of the next annual shareholder meeting.

SEC source: 0001562180-23-003704 · primarydocument.xml · nonDerivative · entry 1

BUTHMAN MARK A · CIK 0001223783 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,222.29

F1 · price: These shares of restricted stock units will vest in full on the date of the next annual shareholder meeting.

SEC source: 0001562180-23-003698 · primarydocument.xml · nonDerivative · entry 1

FRIEL ROBERT F · CIK 0001224110 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,046.98

F1 · price: These shares of restricted stock units will vest in full on the first anniversary of the date of the grant and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors.

SEC source: 0001562180-23-003696 · primarydocument.xml · nonDerivative · entry 1

LAI GOLDMAN MYLA · CIK 0001168581 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,788.93

F1 · price: These shares of restricted stock units will vest in full on the first anniversary of the date of the grant and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors.

SEC source: 0001562180-23-003697 · primarydocument.xml · nonDerivative · entry 1

Pucci Paolo · CIK 0001436861 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,311.95

F1 · price: These shares of restricted stock units will vest in full on the first anniversary of the date of the grant and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors.

SEC source: 0001562180-23-003695 · primarydocument.xml · nonDerivative · entry 1

Joseph Molly · CIK 0001709261 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,248

F1 · price: These shares of restricted stock units will vest in full on the first anniversary of the date of the grant and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors.

SEC source: 0001562180-23-003694 · primarydocument.xml · nonDerivative · entry 1

Keller Deborah L · CIK 0001352992 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,021.72

F1 · price: These shares of restricted stock units will vest in full on the first anniversary of the date of the grant and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors.

SEC source: 0001562180-23-003693 · primarydocument.xml · nonDerivative · entry 1

Michels Douglas A · CIK 0001295391 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,536.05

F1 · price: These shares of restricted stock units will vest in full on the first anniversary of the date of the grant and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors.

SEC source: 0001562180-23-003692 · primarydocument.xml · nonDerivative · entry 1

Feehery William F · CIK 0001543193 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,728.13

F1 · price: These shares of restricted stock units will vest in full on the first anniversary of the date of the grant and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors.

SEC source: 0001562180-23-003040 · primarydocument.xml · nonDerivative · entry 2

Abraham Silji · CIK 0001733001 · SVP, Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,209.2997

F2 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $322.50 to $323.00, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.

SEC source: 0001562180-23-002670 · primarydocument.xml · derivative · entry 7

Green Eric Mark · CIK 0001336007 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 198,132

Underlying: Common Stock · 50,000 shares

Expires 2025-04-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_date: This option is fully vested.

SEC source: 0001562180-23-002670 · primarydocument.xml · nonDerivative · entry 6

Green Eric Mark · CIK 0001336007 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 128,574.0865

F2 · shares: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on 9/14/2022. The Rule 10b5-1 trading plan, which was structured to include several sale periods, was established as part of the Reporting Person's long-term strategy for asset diversification and financial, retirement, estate and tax planning activities over a period of time. In total, 50,000 options were exercised with 44,000 shares sold and 6,000 shares held by the reporting person.

F7 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $324.10 to $324.55, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.

SEC source: 0001562180-23-002670 · primarydocument.xml · nonDerivative · entry 5

Green Eric Mark · CIK 0001336007 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 123,297.0865

F2 · shares: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on 9/14/2022. The Rule 10b5-1 trading plan, which was structured to include several sale periods, was established as part of the Reporting Person's long-term strategy for asset diversification and financial, retirement, estate and tax planning activities over a period of time. In total, 50,000 options were exercised with 44,000 shares sold and 6,000 shares held by the reporting person.

F6 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $323.09 to $324.03, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.

SEC source: 0001562180-23-002670 · primarydocument.xml · nonDerivative · entry 4

Green Eric Mark · CIK 0001336007 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 96,544.0865

F2 · shares: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on 9/14/2022. The Rule 10b5-1 trading plan, which was structured to include several sale periods, was established as part of the Reporting Person's long-term strategy for asset diversification and financial, retirement, estate and tax planning activities over a period of time. In total, 50,000 options were exercised with 44,000 shares sold and 6,000 shares held by the reporting person.

F5 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $322.07 to $323.05, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.

SEC source: 0001562180-23-002670 · primarydocument.xml · nonDerivative · entry 3

Green Eric Mark · CIK 0001336007 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 88,859.0865

F2 · shares: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on 9/14/2022. The Rule 10b5-1 trading plan, which was structured to include several sale periods, was established as part of the Reporting Person's long-term strategy for asset diversification and financial, retirement, estate and tax planning activities over a period of time. In total, 50,000 options were exercised with 44,000 shares sold and 6,000 shares held by the reporting person.

F4 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $321.06 to $322.05, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.

SEC source: 0001562180-23-002670 · primarydocument.xml · nonDerivative · entry 2

Green Eric Mark · CIK 0001336007 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,705.0865

F2 · shares: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on 9/14/2022. The Rule 10b5-1 trading plan, which was structured to include several sale periods, was established as part of the Reporting Person's long-term strategy for asset diversification and financial, retirement, estate and tax planning activities over a period of time. In total, 50,000 options were exercised with 44,000 shares sold and 6,000 shares held by the reporting person.

F3 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $320.06 to $321.05, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.

SEC source: 0001562180-23-002670 · primarydocument.xml · nonDerivative · entry 1

Green Eric Mark · CIK 0001336007 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 135,705.0865

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The shares reported were acquired by the Reporting Person from exercising a portion of a stock option award expiring in 2025, pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was completed pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on 9/14/2022.

SEC source: 0001562180-23-003040 · primarydocument.xml · nonDerivative · entry 1

Abraham Silji · CIK 0001733001 · SVP, Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,709.2997

F1 · kind: Vesting of Bonus & Incentive Grant

SEC source: 0001562180-23-002999 · primarydocument.xml · nonDerivative · entry 1

Birkett Bernard · CIK 0001658001 · Sr VP, CFO & COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,366

F1 · kind: Bonus & Incentive share grant

SEC source: 0001562180-23-001800 · primarydocument.xml · derivative · entry 2

Lai Quintin J · CIK 0001744326 · VP Corp Development & Strategy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,724

Underlying: Stock Options (Right to Buy) · 1,724 shares

Expires 2033-02-21

F2 · derivative.exercise_date: This award vests in four equal annual installments beginning on February 21, 2024.

SEC source: 0001562180-23-001800 · primarydocument.xml · nonDerivative · entry 1

Lai Quintin J · CIK 0001744326 · VP Corp Development & Strategy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,306.93

F1 · shares: 2020 PSUs (PP19) award vesting net of taxes withheld

SEC source: 0001562180-23-001799 · primarydocument.xml · derivative · entry 2

Birkett Bernard · CIK 0001658001 · Sr VP, CFO & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,340

Underlying: Stock Options (Right to Buy) · 10,340 shares

Expires 2033-02-21

F2 · derivative.exercise_date: This award vests in four equal annual installments beginning on February 21, 2024.